Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

por Baron, Kyle T., Macha, Sreeraj, Broedl, Uli C., Nock, Valerie, Retlich, Silke, Riggs, Matthew
Publicado 2016

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients wi...

por Ridderstråle, Martin, Svaerd, Robbyna, Zeller, Cordula, Kim, Gabriel, Woerle, Hans J, Broedl, Uli C
Publicado 2013

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with ty...

por Ferrannini, Ele, Berk, Andreas, Hantel, Stefan, Pinnetti, Sabine, Hach, Thomas, Woerle, Hans J., Broedl, Uli C.
Publicado 2013

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-...

por Nishimura, Rimei, Tanaka, Yuko, Koiwai, Kazuki, Inoue, Kohei, Hach, Thomas, Salsali, Afshin, Lund, Søren S, Broedl, Uli C
Publicado 2015

Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-F...

por Becker, Melanie, Rabe, Katja, Lebherz, Corinna, Zugwurst, Julia, Göke, Burkhard, Parhofer, Klaus G., Lehrke, Michael, Broedl, Uli C.
Publicado 2010

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

por Häring, Hans-Ulrich, Merker, Ludwig, Seewaldt-Becker, Elke, Weimer, Marc, Meinicke, Thomas, Woerle, Hans J., Broedl, Uli C.
Publicado 2013

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

por Ring, Arne, Brand, Tobias, Macha, Sreeraj, Breithaupt-Groegler, Kerstin, Simons, Gudrun, Walter, Beate, Woerle, Hans J, Broedl, Uli C
Publicado 2013

Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome

por Broedl, Uli C, Lehrke, Michael, Fleischer-Brielmaier, Elisabeth, Tietz, Anne B, Nagel, Jutta M, Göke, Burkhard, Lohse, Peter, Parhofer, Klaus G
Publicado 2006

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III r...

por Roden, Michael, Merker, Ludwig, Christiansen, Anita Vedel, Roux, Flavien, Salsali, Afshin, Kim, Gabriel, Stella, Peter, Woerle, Hans J., Broedl, Uli C.
Publicado 2015

Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions

por Lehrke, Michael, Broedl, Uli C, Biller-Friedmann, Ingeborg M, Vogeser, Michael, Henschel, Volkmar, Nassau, Kirsten, Göke, Burkhard, Kilger, Erich, Parhofer, Klaus G
Publicado 2008

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

por Neeland, Ian J., McGuire, Darren K., Eliasson, Björn, Ridderstråle, Martin, Zeller, Cordula, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik
Publicado 2015

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

por Neeland, Ian J, McGuire, Darren K, Chilton, Robert, Crowe, Susanne, Lund, Søren S, Woerle, Hans J, Broedl, Uli C, Johansen, Odd Erik
Publicado 2016

Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

por Neeland, Ian J., McGuire, Darren K., Eliasson, Björn, Ridderstråle, Martin, Zeller, Cordula, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik
Publicado 2018

Predictions for Blockchain in 2020

por Mathew, George T., Porto, Dennis A., Ribitzky, Ron, Ramonat, Susan, Broedl, Uli C., Clauson, Kevin A., Ricotta, Frank, Cenaj, Tory, Ngo, Anh L.
Publicado 2020

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

por Cherney, David ZI, Perkins, Bruce A, Soleymanlou, Nima, Har, Ronnie, Fagan, Nora, Johansen, Odd Erik, Woerle, Hans-Juergen, von Eynatten, Maximilian, Broedl, Uli C
Publicado 2014

Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot

por Mak, Baldwin C., Addeman, Bryan T., Chen, Jia, Papp, Kim A., Gooderham, Melinda J., Guenther, Lyn C., Liu, Yi, Broedl, Uli C., Logger, Marianne E.
Publicado 2021

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

por Inzucchi, Silvio E, Zinman, Bernard, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Hantel, Stefan, Espadero, Rosa-Maria, Woerle, Hans-Jürgen, Broedl, Uli C, Johansen, Odd Erik
Publicado 2015

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial

por Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M., Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.
Publicado 2016

Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques

por Broedl, Uli C., Lebherz, Corinna, Lehrke, Michael, Stark, Renee, Greif, Martin, Becker, Alexander, von Ziegler, Franz, Tittus, Janine, Reiser, Maximilian, Becker, Christoph, Göke, Burkhard, Parhofer, Klaus G., Leber, Alexander W.
Publicado 2009

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

por Zinman, Bernard, Inzucchi, Silvio E., Lachin, John M., Wanner, Christoph, Fitchett, David, Kohler, Sven, Mattheus, Michaela, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik, Albers, Gregory W., Diener, Hans Christoph
Publicado 2017